Spinal cord injury drug trial halted early
NCT ID NCT05965700
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an experimental drug called NVG-291 in people with spinal cord injuries to see if it could help improve movement and strength. The trial was stopped early and included 24 adults with cervical spinal cord injuries. Participants received either the drug or a placebo, and researchers measured changes in nerve signals, walking speed, and hand function.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC SPINAL CORD INJURY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shirley Ryan AbilityLab
Chicago, Illinois, 60611, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could music be medicine for the injured brain?
- Robots join the rehab team: a new hope for regaining movement?
- Can a sugar pill curb the opioid crisis?
- Testosterone may rebuild strength after spinal cord injury — trial puts it to the test
- Can a smart brain implant outsmart chronic pain?
- Can a new rowing seat help veterans with paralysis row freely?